The Irish Pharmaceutical Healthcare Association (IPHA) have introduced reforms to the Irish market with the latest IPHA Agreements, taking effect as of 1st August 2016.
Some of the key changes include:
- Increasing the basket of external reference countries from 9 to 14
- Annual price realignments
- Reduction in the price of off-patented medicines to 50% of the original ex-factory price (80% for biologic medicines) on patent expiry as off 2016
- Rebates of 5.25% for all medicines reimbursed by the HSE from June 2016 to July 2018 and 5.5% from August 2018 to July 2020